Back to Journals » OncoTargets and Therapy » Volume 9

miR-203 facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancer

Authors He S, Zhang G, Dong H, Ma M, Sun Q

Received 17 March 2016

Accepted for publication 8 August 2016

Published 11 October 2016 Volume 2016:9 Pages 6203—6210

DOI https://doi.org/10.2147/OTT.S108712

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ram Prasad

Peer reviewer comments 2

Editor who approved publication: Professor Min Li


Shuqian He, Guihui Zhang, He Dong, Maoqiang Ma, Qing Sun

Department of Pathology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong, People’s Republic of China

Abstract: Breast cancer is the second leading cause of cancer mortality in women worldwide. Molecular therapy is needed to improve the outcome in patients with breast cancer. miR-203 participates in cancer cell proliferation, transformation, and apoptosis. This study showed that miR-203 was upregulated in breast cancer tissues and the MCF-7 cell line. miR-203 knockdown suppressed colony formation and transformation and also limited migration in MCF-7 cells. Fibroblast growth factor 2 (FGF2) was confirmed as a novel target of miR-203, as miR-203 knockdown induced an enhanced expression of FGF2 in MCF-7 cells. Moreover, FGF2 can reverse transforming growth factor-β signal pathway to suppress breast cancer. These findings provide new insights with potential therapeutic applications for the treatment of breast cancer.

Keywords: breast cancer, miR-203, FGF2

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]